GAMP 5 & CSA: Validation You Can Defend, Without the 400-Page Binder

GAMP 5 classifies software into categories that drive the rigour of validation. Category 1: infrastructure software (operating systems, databases as platform components) — IQ only, leveraged from supplier. Category 3: non-configured products used as-is (a label printer driver, a standard antivirus) — risk-based testing of intended use. Category 4: configured products (a commercial eQMS configured to your workflows) — testing of the configuration against intended use, plus reliance on supplier evidence for the core. Category 5: custom applications (bespoke code) — full lifecycle validation. Most companies waste effort by treating every system as Category 5. A modern SaaS eQMS or LIMS is almost always Category 4; the validation effort should be focused on the configuration and the integration, not on retesting features the vendor has already validated.

Both GAMP 5 second edition and FDA CSA put intended use at the centre. The validation effort should be proportionate to the risk that the system, used as intended, could affect product quality, patient safety, or data integrity. Document the intended use clearly — what the system does, who uses it, what decisions depend on its output — and let that drive the test scope. The classic anti-pattern is a 400-page Operational Qualification protocol that exhaustively tests every button on every screen, including features no one in your organisation uses. CSA explicitly says: focus on what's used, focus on what matters, document the rationale for what you didn't test.

FDA CSA's most consequential idea is that critical thinking should drive the testing approach. For low-risk functionality (system displays a non-critical dashboard), unscripted or ad-hoc testing can suffice with the rationale documented. For high-risk functionality (system releases a batch, calculates a dose, controls a CPP), scripted testing with formal expected results is still appropriate. The key is matching the rigour to the risk. The GAMP 5 second edition uses the same logic and reinforces that test evidence can take many forms — screenshots, log captures, recorded sessions, automated test output — not only the traditional executed-protocol with handwritten signatures.

Both standards explicitly endorse leveraging supplier evidence where the supplier is competent and the evidence is appropriate. For a Category 4 system, you should expect your vendor to provide: build validation evidence, code review and security testing summaries, IQ/OQ scripts, release-management evidence, a supplier QMS attestation (often SOC 2 or ISO 9001/27001), and a customer-side validation guide. The leveraging has to be documented — a supplier audit (or a remote questionnaire for lower-risk systems), the supplier evidence reviewed against your acceptance criteria, and your own validation pack referencing the supplier evidence with a rationale for any gaps you addressed yourself.

Validation is not a one-time event. Both GAMP 5 and CSA expect ongoing assurance: periodic review of the system's continued fitness for intended use, change-impact assessment on every configuration or version change, and re-validation triggered by significant changes or by accumulated change drift. The cadence and depth of periodic review should be risk-based — high-risk systems annually with formal review, lower-risk systems on a longer cycle. The most common gap is a system validated at go-live and never reviewed again until an audit finding forces a catch-up cycle two years later. Build periodic review into the QMS calendar, not into someone's task list.

Days 1 to 5: inventory every validated system and classify against the GAMP categories; identify systems treated as Category 5 that are actually Category 4 or 3 (the biggest source of waste). Days 6 to 15: rewrite intended-use statements for the top 10 systems; identify the high-risk functions that warrant scripted testing and the low-risk functions that can move to critical-thinking-based testing under CSA. Days 16 to 25: refresh the validation pack on one pilot system using the leaner approach, with leveraged supplier evidence; measure the page-count and effort delta against the old approach. Days 26 to 30: present to QA and operations leadership; agree the roll-out cadence. Most companies see 60% to 80% reduction in validation effort per system without losing inspectorate defensibility.

FDA inspectors trained on CSA increasingly probe for the rationale behind the validation approach, not just the protocols themselves. Expect questions like: how did you decide what to test? What is the intended use of this system? What evidence did you leverage from the supplier and why? When did you last review this system? Inspectors are not looking to fail companies who used CSA-style critical thinking — they are looking to fail companies whose validation evidence is voluminous but doesn't show why the testing scope was chosen. A 20-page validation pack with a clear intended-use and risk rationale beats a 400-page binder of unsubstantiated test execution.